Marc Nash Sells 5,375 Shares of Outset Medical (NASDAQ:OM) Stock

Outset Medical, Inc. (NASDAQ:OM) EVP Marc Nash sold 5,375 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $27,520.00. Following the completion of the sale, the executive vice president directly owned 42,785 shares of the company’s stock, valued at $219,059.20. This represents a 11.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Marc Nash also recently made the following trade(s):

• On Wednesday, January 21st, Marc Nash sold 980 shares of Outset Medical stock. The stock was sold at an average price of $4.98, for a total transaction of $4,880.40.
• On Wednesday, January 7th, Marc Nash sold 108 shares of Outset Medical stock. The stock was sold at an average price of $4.27, for a total value of $461.16.
• On Monday, November 17th, Marc Nash sold 247 shares of Outset Medical stock. The shares were sold at an average price of $4.60, for a total transaction of $1,136.20.

Outset Medical Price Performance

OM traded up $0.15 during trading on Wednesday, hitting $5.20. 256,678 shares of the company traded hands, compared to its average volume of 1,737,004. The stock’s 50-day simple moving average is $4.34 and its two-hundred day simple moving average is $11.07. Outset Medical, Inc. has a 1 year low of $3.10 and a 1 year high of $21.98. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.77 and a current ratio of 7.09.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on OM shares. Wall Street Zen downgraded Outset Medical from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Stifel Nicolaus lowered their price target on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, January 7th. BTIG Research restated a “buy” rating and set a $17.00 price objective on shares of Outset Medical in a research report on Tuesday, December 16th. Royal Bank Of Canada reissued a “sector perform” rating and set a $7.00 target price on shares of Outset Medical in a research report on Wednesday, December 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Outset Medical in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Outset Medical presently has a consensus rating of “Moderate Buy” and an average target price of $10.67.

Institutional Trading of Outset Medical

Hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc purchased a new stake in shares of Outset Medical during the 2nd quarter worth $34,000. Ameritas Investment Partners Inc. acquired a new position in shares of Outset Medical during the second quarter worth $35,000. BNP Paribas Financial Markets boosted its position in shares of Outset Medical by 7,013.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock worth $40,000 after purchasing an additional 2,034 shares in the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new stake in Outset Medical in the second quarter valued at about $78,000. Finally, New York State Common Retirement Fund acquired a new position in shares of Outset Medical during the second quarter valued at about $108,000.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long?term care facilities and emergency response scenarios.